Deferred Revenues	3 Months Ended
Mar. 31, 2026
Deferred Revenues
Deferred Revenues	10. Deferred Revenues In June 2023, the Company entered into a Supply Agreement with a customer for the delivery of Mo-100 and molybdenum-98 beginning in 2024. In conjunction with the Supply Agreement, the Company received $0.9 million in September 2023, as an advance towards future revenue. The Company has recorded $0.9 million as deferred revenue on the balance sheet as of March 31, 2026 and December 31, 2025. The Company assumed a token liability in connection with the acquisition of Renergen in January 2026. Tokens with the value of $0.8 million were issued during 2023 and have no expiration date. When a token is redeemed, revenue relating to the transaction will be recognized at the original value at which the token was issued. The Company has recorded $0.8 million as deferred revenue - noncurrent on the balance sheet as of March 31, 2026.

Deferred Revenues

3 Months Ended

Mar. 31, 2026

10. Deferred Revenues

In June 2023, the Company entered into a Supply Agreement with a customer for the delivery of Mo-100 and molybdenum-98 beginning in 2024. In conjunction with the Supply Agreement, the Company received $0.9 million in September 2023, as an advance towards future revenue. The Company has recorded $0.9 million as deferred revenue on the balance sheet as of March 31, 2026 and December 31, 2025.

The Company assumed a token liability in connection with the acquisition of Renergen in January 2026. Tokens with the value of $0.8 million were issued during 2023 and have no expiration date. When a token is redeemed, revenue relating to the transaction will be recognized at the original value at which the token was issued. The Company has recorded $0.8 million as deferred revenue - noncurrent on the balance sheet as of March 31, 2026.